• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Baxter BioPharma Solutions

    Alcami

    Reed-Lane

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Reed-Lane

    Alcami

    Flow Sciences

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing

    What does a one-stop shop really mean and is it always best for the client?

    The Evolution of the ‘One-Stop Shop’  in Clinical Supplies Sourcing
    The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing
    Related CONTENT
    • Hovione Launches ASD-HIPROS
    • Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    • Oligonucleotides
    • CHA Biotech Launches Global CDMO Biz
    • Catalent Appoints Minakuchi Facility GM
    Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions05.05.16
    In today’s pharmaceutical market, innovation and speed-to-clinic are more critical than ever. Small companies and specialty pharma players are increasingly relied upon to deliver these important requirements within the industry. One area attracting increased focus is these companies’ outsourcing capabilities, including drug design, development and clinical supply sourcing. 

    Many of these contract development and manufacturing organization (CDMO) companies are promoting themselves as a “one-stop shop,” but what does this really mean and is it always best for the client? Sure, pharmaceutical companies would like to deal with one CDMO who can address any problem statement optimally and service them from point A to point B. However, there is a wide range of product design capabilities amongst CDMO players, and an even larger range of process design capabilities, which can be critical in scaling a product concept and bringing it to market. And to optimize a product concept, a CDMO must have a range of enabling technologies to address specific problem statements, vs. stretching a single technology’s boundaries. Specialized handling capabilities are also often required, such as the case with high containment isolation. 

    These factors must all be taken into consideration when evaluating one-stop shop and speed to clinic claims. 

    Clinical supply sourcing is such a broad capability and involves many moving parts. So how should a client choose between potential partners? What sets each CDMO apart as a clinical solutions provider?

    1. Design and Preformulation and Formulation Development
    While many CDMOs have strong manufacturing roots, a smaller number have historical development, and before that, design capabilities. Effective design has dependencies on both project approach—including the ability to fully define the problem statement(s), and tailor a solution based on meeting the target product profile (TPP) and commercial objectives—as well a technology range to facilitate that approach.

    Successful pre-formulation and formulation development hinges on several key factors, including efficient feasibility assessments, technology breadth for formulation optimization, and phase-appropriate equipment to accommodate early stage development work through to manufacturing the first clinical supply. 

    In the early stages of the development cycle of an API, feasibility screening is critical and the supply of API can be very precious. Ideally, a comprehensive pre-formulation evaluation is completed on the API prior to the initiation of the formulation development work. This work-up includes characterizations, such as polymorph studies, pH solubility profiles, moisture absorption/desorption profiles, particle shape and particle size distribution. All of the information gathered at this stage will be helpful in the later stages of the development process.

    Access to a range of technologies for addressing key formulation challenges is critical for formulation design optimization and scale-up. If a CDMO is not well versed with the range of technologies available for meeting a target product profile and addressing a given set of formulation challenges, a sub-optimal formulation may result which can cause further delays. If a service provider’s experience is primarily in using a ‘hammer’ to address a particular challenge such as low solubility, then all problems will appear as ‘nails’ potentially to the detriment of the client’s compound. 

    Developing fit for purpose formulations is an important need in early stage evaluations, with formulation optimization and scale-up done after successful demonstration of feasibility. Small-scale equipment is available to do feasibility work. For some processes, proprietary lab-scale processing equipment has been developed and fabricated to accommodate early feasibility work, such as pharmaceutical spray dryers, wet milling equipment and jet mills. This equipment has proven valuable for successful feasibility assessments with minimal bulk API usage—as little as 200mg.

    An additional key tool is the use of Capsugel’s Xcelodose Precision Powder Micro-Dosing System to manufacture clinical supplies for early clinical studies. There are two main approaches for developing Phase I clinical supplies for oral solids: the traditional approach and the use of Xcelodose Systems. The traditional approach requires development of a formulated tablet or capsule and necessitates a significant amount of API and time for the development of a stable formulation. There is limited ability to make adjustments if there is a change in the required dosage strength(s). The more complicated the formulation, the more time and quantity of API is necessary to complete the work. An alternative is to use the Xcelodose Systems to fill the API directly into capsule shells without the use of any additional excipients. This approach allows for more flexibility in the number of strengths that can be manufactured, using a minimal amount of API. The strength(s) to be manufactured can be changed late in the development cycle, closer to the time of clinical supply manufacture, without serious consequences. Using Xcelodose Systems also limits stability concerns, and can cut months off of the time it takes to prepare for a Phase I study. If the Phase I study is successful, then a more traditional formulation can be formulated to be ready to start Phase II clinical trials. 

    2. cGMP Manufacturing
    In the clinical supplies arena of cGMP manufacturing, there are many suitable platforms that can be used in the development process of an oral dosage form. The need for specialized delivery among dosage forms is now the norm. Compressed tablets are still the primary dosage form of choice but they come in many forms. Single layer tablets are developed for immediate release as well as modified (delayed or sustained) release profiles. The modified release tablet can be a matrix blend of polymer and excipients or coated in order to achieve the desired release profile. On occasion, the combination of a matrix blend and coating are required. The blend formulation can be achieved by direct blending, high or low shear granulation, dry granulation (roller compaction or slugging) and fluid bed granulation. Bi-layer tablets are also a popular choice for modified release tablets in which one layer constitutes the immediate release portion, and the second layer provides a modified release dose. The use of bi-layer tablets is also an appropriate choice for combination products in which the active ingredients may be incompatible. Other tablet forms, such as orally disintegrating tablets (ODTs) and osmotic tablets may be suitable delivery platforms depending on the therapeutic need.

    An alternative to compressed tablets is multiparticulate (MP) dosage forms. The use of MP technologies can be extremely useful in targeted delivery and release rates within the body. Coated spherules can be achieved by layering the drug substance and coatings onto a substrate pellet. Various coatings are then applied to ensure release in certain targeted areas of the body. An alternative to coated spherules is sphere production by means of extrusion and spheronization (ES). ES allows the formulation of dense pellets that contain a significant portion of drug substance as part of the matrix. The big advantage of ES is the increase in drug load per pellet as compared to coated spherules. This reduces the overall pellet fill weight and ultimately the size of the capsule, which is desirable for patient compliance. Another multi-particulate technology is lipid multiparticulates (LMP). This involves dissolution of the drug substance in a lipid matrix, which is then transformed into pellets through a melt-spray-congeal process. LMP is especially beneficial for improvement in bioavailability and offers high drug loading. LMP spheres can also be coated for additional release control. MP and LMP coating is achieved through the use of bottom-spray (Wurster) insert contained within a fluid bed processor.

    All MP platforms can be encapsulated into a standard two-piece capsule or filled into a sprinkle capsule for pediatric and older adult applications where dysphagia may be an issue. It is also possible to fill multiple pellets within a single capsule to achieve the desired dosing. Other capsule-filling options include powder, pellets/powder, tablet/powder and micro-dosing of powder. Another unique approach is liquid fill into a hard two-piece capsule. For more challenging molecules, it is possible to dissolve or suspend the API within a simple lipid-based matrix and fill this mixture into a two-piece capsule. The capsule can also be filled using a hot-melt formulation, which solidifies at room temperature. Once the capsules are filled and closed, they are sealed using liquid encapsulation micro-spray (LEMS) or banding process. The liquid-filled two-piece capsule is beneficial for improving drug bioavailability.

    3. Quality
    From a quality perspective, there are three areas related to clinical supplies sourcing where CDMOs differentiate themselves.

    The “little c”: The little-c in cGMP represents the notion that the industry and regulators will never be satisfied with the “current” state of business. Pharma quality is always trying to keep up with or drive the next incremental improvement.  The sharp operators will try to advance the little-c to create competitive advantage, and there exists a dynamic tension between industry and government as to who is going to define the new standard.  Serialization and DSCSA is a great example of the little-c, and how industry and regulators are advancing these standards. 

    Rich and diverse regulatory landscape: The complex regulatory environment drives the industry to default to the highest standard, not the minimal or least burdensome approach. The reality of the CDMO business is it must operate at a global level to remain competitive, and harmonize policies, procedures and practices to comply with multiple regulatory standards. Where those standards overlap, leading CDMOs are taking the most conservative standard and creating policy to meet that standard. Where standards do not overlap, these CDMOs are creating new policies to comply with those unique requirements associated with a single market. 

    Control of outsourced processes: As CDMOs become more specialized and more technically competent in certain areas, often the outsourced projects are already outsourced. Higher risk outsourcing includes contract labs and subcontracted manufacturing/packaging/distribution operations. Ensuring these are under control requires both a high-touch, look-often philosophy. Convincing clients and regulators that outsourced processes are under control necessitates extensive and frequent documentation and a demonstrated willingness by the CDMO to walk away from a supplier that can’t manage its expectations.

    4. Packaging and Labeling
    Specialty companies like Capsugel bring a similar range of capabilities to clinical supplies sourcing. Xcelience deliberately chose the term clinical supplies solutions over service because it firmly believes that its team of clinical packaging professionals brings much more than just a service to a project. Clinical supply is more than simply putting a sticker on a bottle. It requires a wide range of skills to make the most efficient and compliant patient supplies.

    The solutions provided are based upon interpretation of the protocol and the construction of a comprehensive project plan that incorporates elements such as label design, text translations, component selection and carton/insert/wallet arrangements, in addition to essential platforms such as the randomization, temperature conditions, and sensitivity to light. To help support temperature-sensitive products, secondary packaging under refrigerated conditions (2°C-8°C) is available to minimize time outside of this condition. 

    A large feature of this ability is moving bulk product, literally hot-off-the-press, from the manufacturing room directly to the packaging group under a conditional release. This conditional status allows the movement of material forward, but also prevents it from inappropriate issuance or dispatch. This feature drastically reduces overall timelines because there is no time lag between bulk product manufacture and packaging of finished goods. The packaging can be completed and the product approved for release to meet even the most aggressive timelines. 

    In choosing a CDMO for clinical supply sourcing, pharmaceutical companies should evaluate the strength of their potential partner’s capabilities across each of the design, development and manufacturing phases. Partners with deep experience and know-how specific to design and development, as much as manufacturing, should be preferred. Further, partners with a depth of technology capabilities to address certain problem statements—including solubility issues, site delivery and pediatric dosage forms for oral solid delivery—and the ability to commercially manufacture those technologies, will likely help lead to the best possible product outcome. The “one-stop shop” is a worthy partner, but only if the CDMO truly lives up to that name. 
    Related Searches
    • Outsourcing
    • Phase I
    • formulation
    • Phase II
    Suggested For You
    Hovione Launches ASD-HIPROS Hovione Launches ASD-HIPROS
    Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    Oligonucleotides Oligonucleotides
    CHA Biotech Launches Global CDMO Biz CHA Biotech Launches Global CDMO Biz
    Catalent Appoints Minakuchi Facility GM Catalent Appoints Minakuchi Facility GM
    Recipharm Expands API Manufacturing Capabilities Recipharm Expands API Manufacturing Capabilities
    Batavia Biosciences Batavia Biosciences
    Sharp Implements Cloud-Based QMS Sharp Implements Cloud-Based QMS
    Bionova Scientific Secures First Client Commitment Bionova Scientific Secures First Client Commitment
    Recro Gainesville Recro Gainesville
    A Potential “Marriage” A Potential “Marriage”
    CDMOs: Keeping up with Science & Technology CDMOs: Keeping up with Science & Technology
    Axcellerate Pharma, LLC Axcellerate Pharma, LLC
    Catalent, BrainStorm Enter ALS Drug Manufacturing Pact Catalent, BrainStorm Enter ALS Drug Manufacturing Pact
    Vetter continues its long-term investment strategy to sustain future growth Vetter continues its long-term investment strategy to sustain future growth

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20


    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19


    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Formulation Development
      Developing Faster-to-Clinic Formulations

      Developing Faster-to-Clinic Formulations

      When standard formulation strategies fail, is there a fast path to clinic for hard-to-formulate therapeutics?
      Phil Morton, Chief Technology Officer, Albumedix 06.12.18

    • Formulation Development
      Formulation Development Trends

      Formulation Development Trends

      Innovation in formulation development continues to be driven by the need to improve drug bioavailability.
      Torkel Gren, General Manager, Recipharm Pharmaceutical Development AB 04.10.18

    • Formulation Development | Preclinical Outsourcing
      Formulating Candidates  with Bioavailability Issues

      Formulating Candidates with Bioavailability Issues

      To avoid the solubility pitfalls that too often halt a medicines progress from clinic to market, it’s vital to start formulat
      Stephen Tindal, Director - Science and Technology, Catalent 05.09.17


    • Clinical Trials
      Tracking Health

      Tracking Health

      Exploring the impact of wearable health monitoring tools on CROs
      Nigel Walker 05.09.17

    • Drug Development | Formulation Development
      Formulation Strategies for  Aging Consumers

      Formulation Strategies for Aging Consumers

      Convenience, flavor and novel combinations of ingredients can help offer better product experiences.
      Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions 03.07.17

    • Drug Development | Formulation Development
      Modeling & Simulation for  Drug Development & Formulation

      Modeling & Simulation for Drug Development & Formulation

      A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
      Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • The Future Of Clinical Trials Series: Part I
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    Associations Congratulate Biden & Harris
    David Stanko Joins JPMS
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login